<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Clinical presentation and diagnostic evaluation of ventilator-associated pneumonia</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Clinical presentation and diagnostic evaluation of ventilator-associated pneumonia</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Clinical presentation and diagnostic evaluation of ventilator-associated pneumonia</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Marin H Kollef, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Scott Manaker, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Geraldine Finlay, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 13, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Ventilator-associated pneumonia (VAP) is a type of hospital-acquired pneumonia (HAP) that develops after more than 48 hours of mechanical ventilation [<a href="#rid1">1</a>]. VAP is a common and serious problem in the intensive care unit that is associated with an increased risk of death. Accurate diagnosis is important so that appropriate treatment can be instituted early while simultaneously avoiding antibiotic overuse and consequently, antibiotic resistance.</p><p>Patients with severe HAP who require mechanical ventilation <strong>after</strong> the onset of infection do not meet the definition of VAP. This is termed ventilated hospital-acquired pneumonia (VHAP) [<a href="#rid1">1</a>]. However, the microbiology, diagnostic evaluation, and outcomes of VHAP are more similar to VAP than HAP [<a href="#rid1">1-4</a>]. The clinical presentation and diagnosis of VAP are reviewed here. The epidemiology, pathogenesis, and risk factors for VAP as well as its prevention and treatment are discussed separately. (See  <a class="medical medical_review" href="/d/html/6993.html" rel="external">"Treatment of hospital-acquired and ventilator-associated pneumonia in adults"</a> and  <a class="medical medical_review" href="/d/html/6995.html" rel="external">"Risk factors and prevention of hospital-acquired and ventilator-associated pneumonia in adults"</a> and  <a class="medical medical_review" href="/d/html/1656.html" rel="external">"The ventilator circuit"</a>.)</p><p class="headingAnchor" id="H340210395"><span class="h1">CLINICAL PRESENTATION</span></p><p class="headingAnchor" id="H845205575"><span class="h2">Clinical features</span><span class="headingEndMark"> — </span>Most patients with VAP present with a gradual or sudden onset of the following more than 48 hours after intubation [<a href="#rid5">5</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Symptoms – dyspnea (few patients have symptoms since most are nonverbal on mechanical ventilation)</p><p class="bulletIndent1"><span class="glyph">●</span>Signs – fever, tachypnea, increased or purulent secretions, hemoptysis, rhonchi, crackles, reduced breath sounds, bronchospasm</p><p class="bulletIndent1"><span class="glyph">●</span>Ventilator mechanics – reduced tidal volume, increased inspiratory pressures</p><p class="bulletIndent1"><span class="glyph">●</span>Laboratory findings – worsening hypoxemia, leukocytosis</p><p class="bulletIndent1"><span class="glyph">●</span>Imaging – new or progressive infiltrate on chest radiograph or computed tomography (CT) (see <a class="local">'Chest imaging'</a> below)</p><p></p><p>Features may also be accompanied by systemic abnormalities, such as encephalopathy or sepsis. (See  <a class="medical medical_review" href="/d/html/1657.html" rel="external">"Sepsis syndromes in adults: Epidemiology, definitions, clinical presentation, diagnosis, and prognosis", section on 'Sepsis'</a>.)</p><p>Importantly, as isolated findings, none of these features are sensitive or specific for the diagnosis of VAP [<a href="#rid6">6</a>]. In particular, fever and respiratory distress are common among intubated patients with a wide variety of etiologies that must also be considered. (See  <a class="medical medical_review" href="/d/html/1624.html" rel="external">"Fever in the intensive care unit"</a> and  <a class="medical medical_review" href="/d/html/1633.html" rel="external">"Assessment of respiratory distress in the mechanically ventilated patient"</a>.)</p><p class="headingAnchor" id="H3512627919"><span class="h2">Chest imaging</span><span class="headingEndMark"> — </span>We obtain a chest radiograph on all patients with suspected VAP [<a href="#rid1">1,7</a>]. A diagnosis of VAP cannot be made without the identification of an infiltrate on chest imaging, particularly one where the filtrate is new or progressive. Common radiographic abnormalities in VAP include alveolar infiltrates, air bronchograms, and silhouetting of adjacent solid organs. The chest radiograph can also help determine the severity of the disease (multilobar versus unilobar) and identify complications, such as pleural effusions or cavitation.</p><p>Chest imaging abnormalities alone are insufficient to diagnose VAP because the findings are nonspecific (ie, imaging is frequently abnormal even in the absence of VAP). This was illustrated by an observational study in which only 43 percent of patients who had clinical and radiographic evidence of VAP at the time of their death were subsequently confirmed to have VAP by postmortem examination [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H2756495"><span class="h1">DIAGNOSTIC EVALUATION</span><span class="headingEndMark"> — </span>VAP should be suspected in patients with a new or progressive pulmonary infiltrate on imaging PLUS supportive clinical findings of infection (eg, fever, secretions, leukocytosis) (see <a class="local">'Clinical presentation'</a> above). The diagnosis is confirmed when lower respiratory tract sampling identifies a pathogen. (See <a class="local">'Diagnosis'</a> below.)</p><p class="headingAnchor" id="H1282532654"><span class="h2">Advanced imaging</span><span class="headingEndMark"> — </span>Chest CT, without contrast, is not routine in patients with suspected VAP but may be useful in patients with a normal chest radiograph who have clinical symptoms of respiratory tract infection (eg, patients with fever plus leukocytosis and purulent tracheobronchial secretions). CT may also help identify a target lobe for sampling. Chest CT may also be appropriate in those with a previous CT diagnosis of pneumonia to look for new or progressive changes or the development of a pleural effusion. However, in mechanically ventilated patients, pulmonary infiltrates are frequently identified and may be associated with multiple causes. Therefore, imaging determination of VAP in the critical care setting remains nonspecific [<a href="#rid7">7,8</a>]. Lung ultrasonography may be more useful for ruling out pneumonia, although subpleural consolidations and dynamic air bronchograms may support VAP [<a href="#rid9">9</a>]. Bedside ultrasound can also be employed to diagnose VAP, although whether it leads to improved outcomes over conventional chest imaging is unknown [<a href="#rid10">10</a>].</p><p class="headingAnchor" id="H132997803"><span class="h2">Respiratory tract sampling</span></p><p class="headingAnchor" id="H358470086"><span class="h3">Timing of sampling and empiric antibiotics</span><span class="headingEndMark"> — </span>Respiratory samples are ideally obtained <strong>prior</strong> to the initiation of antibiotics or change of antibiotic therapy (in those already receiving antibiotics), because antibiotic therapy reduces the sensitivity of both the microscopic analysis and culture [<a href="#rid11">11-14</a>]. However, not uncommonly, severe illness or delays in sampling requires that empiric antibiotic therapy be initiated prior to diagnostic sampling. Nonetheless, once respiratory specimens have been obtained, empiric antibiotic therapy is indicated for suspected VAP, targeting the suspected organism using local antibiograms  (<a class="graphic graphic_algorithm graphicRef132505" href="/d/graphic/132505.html" rel="external">algorithm 1</a>), the details of which are discussed separately. (See  <a class="medical medical_review" href="/d/html/6993.html" rel="external">"Treatment of hospital-acquired and ventilator-associated pneumonia in adults", section on 'Empiric therapy'</a>.)</p><p class="headingAnchor" id="H826097128"><span class="h3">Respiratory tract sample type</span><span class="headingEndMark"> — </span>Most experts agree that in patients with suspected VAP, the lower respiratory tract should be sampled and peripheral blood cultures should be sent. However, experts disagree on how the respiratory sample should be obtained (invasive versus noninvasive sampling) and whether or not cultures should be quantitative or nonquantitative.</p><p class="headingAnchor" id="H4131106291"><span class="h4">Our preferred approach</span><span class="headingEndMark"> — </span>The authors favor the approach set out by the 2017 guidelines issued by The European Respiratory Society (ERS)/European Society of Intensive Care Medicine (ESCIM)/European Society of Clinical Microbiology/Infectious Diseases (ESCMID)/Asociación Latinoamericana del Tórax (ALAT), which state a preference for invasive sampling methods (eg, mini-bronchoalveolar lavage [BAL], bronchoscopic BAL, or protected specimen brush [PSB]) with quantitative cultures [<a href="#rid2">2</a>]. This preference is based upon the high value that we place on diagnostic accuracy and the potential to reduce antibiotic exposure, thereby promoting good antibiotic stewardship when compared with noninvasive sampling (ie, endotracheal aspiration) and nonquantitative cultures. In contrast, other experts prefer the approach set forth by The Infectious Diseases Society of America/The American Thoracic Society, which state a preference for noninvasive sampling with semiquantitative cultures for the diagnosis of VAP [<a href="#rid1">1,15</a>]; this preference is based upon evidence that demonstrates no difference in mortality or length of stay with either approach [<a href="#rid16">16</a>]. (See <a class="local">'Alternative approach'</a> below.)</p><p>However, practice varies widely and is often institution-, physician-, and patient-specific. The wide variation in practice is partially explained by a lack of gold standard for the diagnosis of VAP [<a href="#rid17">17</a>] and differences in opinion regarding the relative importance of specific clinical outcomes (mortality, length of stay, antibiotic resistance). Additional factors include the ability of the patient to tolerate invasive sampling, and the presence of other indications for bronchoscopy (eg, endobronchial obstruction, bleeding, cancer, invasive pneumonia in an immunosuppressed patient, suspicion for a second organism [eg, patients with bronchiectasis], noninvasive methods are unhelpful), available expertise, and institutional availability and cost of quantitative cultures. As an example, while bronchoscopy may be preferred in an immunosuppressed patient with hemoptysis, endotracheal aspiration may be preferred in patients in whom the suspicion for VAP is low or in whom the risk of bronchoscopy is high (eg, patients with barotrauma, high peak pressures, severe hypoxemia). (See <a class="local">'Society guideline links'</a> below.)</p><p class="headingAnchor" id="H2673132852"><span class="h5">Invasive respiratory sampling</span><span class="headingEndMark"> — </span>Invasive methods of sampling generally involve nonbronchoscopic methods (eg, mini-BAL) or bronchoscopic methods (eg, bronchoscopic BAL or PSB) [<a href="#rid18">18-26</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Bronchoscopic BAL is our preferred method of lower respiratory tract sampling. The rationale for this approach is that BAL, compared with PSB (and probably mini-BAL), is a larger sample that obtains a dominant alveolar component with minimal airway contamination. When compared with noninvasive sampling techniques (endotracheal aspirates), bronchoscopic sampling has been shown in several studies to reduce antibiotic overuse and result in more rapid de-escalation of antimicrobial therapy without impacting mortality or length of stay [<a href="#rid27">27-30</a>] (see <a class="local">'Efficacy'</a> below). A larger sample is also especially helpful in immunocompromised patients where additional microbiologic studies are typically warranted. In addition, cytospin and differential cell count can be performed on BAL fluid which may be helpful in non-neutropenic hosts where the identification of less than 50 percent neutrophils would make acute bacterial pneumonia unlikely. Additional advantages include the ability to inspect the airways for purulence and exclude conditions like malignancy and hemorrhage. PSB is an alternative to BAL. Rarely, both BAL and PSB are obtained, in which case many experts do the PSB first.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>BAL involves the infusion and aspiration of sterile <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> through a flexible bronchoscope that is wedged in an affected bronchial segmental or subsegmental orifice (eg, fourth order bronchus  (<a class="graphic graphic_figure graphicRef104076" href="/d/graphic/104076.html" rel="external">figure 1</a>)). The technique of bronchoscopy and BAL are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/4303.html" rel="external">"Basic principles and technique of bronchoalveolar lavage"</a> and  <a class="medical medical_review" href="/d/html/105799.html" rel="external">"Flexible bronchoscopy in adults: Preparation, procedural technique, and complications"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>PSB is a brush that is contained within a protective sheath, which minimizes the likelihood that the brush will be contaminated during bronchoscopy. The procedure involves placing the bronchoscope tip next to the affected bronchial segmental orifice, pushing the sheath through the bronchoscope under direct visual guidance, and then advancing the brush out of the sheath and into the airway. Specimens are collected by brushing the airway wall, withdrawing the brush into the sheath, and then removing the sheath from the bronchoscope. The distal end of brush can be cut and sent for microscopic analysis and culture.</p><p></p><p class="bulletIndent1">One disadvantage of bronchoscopic sampling is that it is only performed by physicians with expertise in the procedure and cannot be performed by ancillary staff. In addition, it is more invasive and ventilated patients are at risk of complications including worsening hypoxemia and barotrauma. However, indirect data suggest that the invasive approach incurs minimal added risk to the patient, although these data are likely influenced by selection bias in favor of bronchoscopy [<a href="#rid31">31,32</a>]. (See  <a class="medical medical_review" href="/d/html/1592.html" rel="external">"Diagnosis, management, and prevention of pulmonary barotrauma during invasive mechanical ventilation in adults"</a> and  <a class="medical medical_review" href="/d/html/4398.html" rel="external">"Flexible bronchoscopy in adults: Overview"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mini-BAL is performed by advancing a catheter through the endotracheal tube blindly until resistance is met, infusing sterile <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> through the catheter (typically three 50 mL aliquots), and then aspirating using the syringe (the catheter is estimated to be located in the distal endobronchial airway [eg, second or third order bronchus  (<a class="graphic graphic_figure graphicRef104076" href="/d/graphic/104076.html" rel="external">figure 1</a>)]). We generally reserve mini-BAL for those in whom bronchoscopy is too risky or not available. This procedure requires less expertise and training than bronchoscopy and it is often performed by ancillary staff (eg, nurses and respiratory therapists) rather than clinicians. Complications are rare but include hypoxemia, endobronchial perforation, and barotrauma. While mini-BAL samples are likely to be less contaminated by the airway than endotracheal aspirates, they are less likely to contain a deep alveolar sample [<a href="#rid20">20,33</a>]. Supporting its role as an alternative to bronchoscopic-BAL is a meta-analysis of six studies where patients underwent both mini- and bronchoscopic-BAL in succession [<a href="#rid34">34</a>]. The reported sensitivity of mini-BAL for VAP was 0.9 (95% CI 0.78-1) and specificity was 0.83 (95% CI 0.72-0.94). However, interpretation is limited due to variations in volume of saline used and heterogeneity of patients studied.</p><p></p><p class="headingAnchor" id="H4034120423"><span class="h5">Microscopic analysis and quantitative culture</span><span class="headingEndMark"> — </span>All respiratory tract samples should be sent for microscopic analysis and our preference is that quantitative cultures be obtained:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Microscopic analysis</strong> – This involves semi-quantitative analysis of polymorphonuclear leukocytes and other cell types, as well as the Gram stain. While not diagnostic of VAP per se, the microscopy results return before cultures and can be helpful in determining a possible pathogen and alter antibiotic selection [<a href="#rid35">35</a>]. The presence of abundant neutrophils is consistent with VAP and the bacterial morphology may suggest a likely pathogen (eg, Gram-negative rods). In a prospective cohort study of 39 patients who underwent BAL, VAP was correctly excluded in all patients in whom neutrophils were fewer than 50 percent of the total nucleated cells [<a href="#rid36">36</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Quantitative cultures</strong> – Bacteria can be counted on any respiratory specimen. VAP is supported when an established threshold of bacterial growth is exceeded [<a href="#rid37">37</a>]. Only bacteria that are pulmonary pathogens should be counted. As examples, Staphylococcus epidermidis and most Gram-positive bacilli (except actinomycosis and nocardia) should not be counted.</p><p></p><p class="bulletIndent1">Typical thresholds include the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Endotracheal aspirates – ≥1,000,000 colony forming units (cfu)/mL</p><p class="bulletIndent2"><span class="glyph">•</span>Bronchoscopic- or mini-BAL – 10,000 cfu/mL</p><p class="bulletIndent2"><span class="glyph">•</span>PSB – 1000 cfu/mL</p><p></p><p class="bulletIndent1">These thresholds are considered sufficiently high that patients with tracheobronchial colonization are unlikely to be mistakenly detected as having VAP (ie, low false-positive rate) [<a href="#rid13">13,38</a>].</p><p></p><p class="bulletIndent1">Lower thresholds are accepted by some experts if it is felt that the risk of missing VAP (ie, a false-negative result) exceeds the risk of unnecessary treatment (ie, a false-positive result) [<a href="#rid39">39</a>]. For example, in a prospective cohort study of 122 patients with suspected VAP, thresholds between 1000 and 10,000 cfu/mL for BAL specimens and between 100 and 1000 cfu/mL for PSB specimens increased the sensitivity (77 to 87 percent for BAL and from 67 to 81 percent for PSB) without significantly decreasing the specificity (from 77 to 73 percent for BAL and from 88 to 84 percent for PSB) [<a href="#rid40">40</a>].</p><p></p><p class="bulletIndent1">Generally speaking, compared with quantitative cultures derived from bronchoscopic specimens, quantitative cultures derived from <strong>non</strong>bronchoscopic specimens have similar or higher diagnostic sensitivity (ie, low false negative rate) but a lower specificity (ie, higher false-positive rate) [<a href="#rid20">20,22</a>]. For example in a prospective cohort study of 38 patients, the sensitivity was highest for endotracheal aspirates (87 percent), and lower for mini-BAL (67 percent), bronchoscopic BAL (58 percent), and PSB (42 percent) [<a href="#rid20">20</a>].</p><p></p><p class="bulletIndent1">Quantitative cultures are not routinely performed in most laboratories, unless specifically requested. They are generally considered more labor-intensive and more costly than qualitative or semiquantitative cultures.</p><p></p><p class="bulletIndent1">Quantifying anaerobes typically follow the same rules, but take longer and need specific laboratory expertise such that few laboratories perform it.</p><p></p><p class="headingAnchor" id="H2724942608"><span class="h5">Efficacy</span><span class="headingEndMark"> — </span>Data that support invasive sampling with quantitative cultures include mostly observational data and small randomized trials that report an increased number of antibiotic-free days and a reduction in the over-identification of VAP, when compared with less invasive techniques:</p><p class="bulletIndent1"><span class="glyph">●</span>In one study of 413 patients with suspected VAP, compared with noninvasive sampling (eg, endotracheal aspiration) with nonquantitative cultures, an invasive quantitative strategy (BAL or PSB) combined with an algorithm for treatment de-escalation resulted in a reduction in mortality at day 14 (16 versus 26 percent) as well as reduced antibiotic use (mean number of antibiotic-free days, 5 versus 2.2 at 14 days and 11.5 versus 7.5 at 28 days) and organ failure scores [<a href="#rid28">28</a>]. Randomized trials and a meta-analysis performed since then have not shown any difference in mortality, length of stay, or antibiotic-free days [<a href="#rid41">41,42</a>]. However, there were no antimicrobial de-escalation protocols in those studies which may have affected the data on antibiotic use. These data are discussed in detail separately. (See <a class="local">'Noninvasive respiratory sampling'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a prospective trial of 155 patients with suspected VAP, bronchoscopic quantitative methods of sampling were associated with a reduction in the number of samples in which bacteria were identified (43 versus 86 percent) and led to a reduction in antibiotic use when compared with noninvasive sampling methods [<a href="#rid43">43</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In an observational study of 89 patients with clinically suspected VAP and a negative (&lt;10<sup>4</sup> colony forming units/mL) quantitative BAL, early discontinuation of antibiotics (within one day) resulted in fewer superinfections (23 versus 43 percent), respiratory superinfections (10 versus 29 percent), and multidrug resistant superinfections (8 versus 36 percent), compared with patients in whom antibiotics were discontinued later than one day [<a href="#rid44">44</a>].</p><p></p><p class="headingAnchor" id="H1484279637"><span class="h4">Alternative approach</span><span class="headingEndMark"> — </span>Noninvasive sampling (ie, endotracheal aspirates) with semiquantitative cultures (or less commonly, qualitative cultures) is the alternative approach preferred by The Infectious Diseases Society of America/The American Thoracic Society [<a href="#rid1">1,15</a>]. This preference is based upon the lack of clear evidence demonstrating superior outcomes (mortality or length of stay) with this approach compared with invasive sampling and quantitative cultures (described above) [<a href="#rid16">16</a>]. (See <a class="local">'Our preferred approach'</a> above.)</p><p class="headingAnchor" id="H322290"><span class="h5">Noninvasive respiratory sampling</span><span class="headingEndMark"> — </span>Tracheobronchial aspiration (ie, endotracheal aspirate) is performed by advancing a catheter through the endotracheal tube until resistance is met and suction is applied (likely located in trachea or main stem bronchus  (<a class="graphic graphic_figure graphicRef104076" href="/d/graphic/104076.html" rel="external">figure 1</a>)). The sample is directly aspirated into a sterile specimen trap that can be sent for microbiologic analysis  (<a class="graphic graphic_picture graphicRef116757" href="/d/graphic/116757.html" rel="external">picture 1</a>).</p><p>A clinician is not necessary to perform or supervise tracheobronchial aspiration. This method is cheap, safe, efficient, and facilitates serial sampling. However, it may be less accurate for sampling the alveolar component of the lower respiratory tract and lead to the over diagnosis of VAP. It may also be less suitable for patients with invasive pneumonia who are immunocompromised. (See <a class="local">'Efficacy'</a> above.)</p><p class="headingAnchor" id="H2880346066"><span class="h5">Microscopic analysis and nonquantitative culture</span></p><p class="bulletIndent1"><span class="glyph">●</span>Microscopic analysis is standard for all respiratory samples and is described above. (See <a class="local">'Microscopic analysis and quantitative culture'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Semiquantitative cultures are typically reported as showing heavy, moderate, light, or no bacterial growth. The amount of growth suggests VAP has not been firmly established, but most experts consider moderate or heavy growth to be positive. Compared with quantitative cultures, semiquantitative cultures are less likely to distinguish patients whose airways are colonized from those who have VAP [<a href="#rid16">16,45</a>]. As a result, false-positive results are more likely, which can potentially lead to over treatment of VAP. Semiquantitative cultures are generally less labor intensive than quantitative cultures and less costly.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Qualitative cultures do not specify the amount of bacterial growth. VAP is considered to be present when a sample is positive. Their diagnostic utility has not been directly compared with semiquantitative or quantitative cultures.</p><p></p><p class="headingAnchor" id="H928393377"><span class="h5">Efficacy</span><span class="headingEndMark"> — </span>Noninvasive sampling with semiquantitative cultures has not been shown to affect important clinical outcomes when compared with quantitative invasive techniques [<a href="#rid16">16,27-29,41,46,47</a>]. This was best illustrated in a meta-analysis of three randomized trials (1240 patients), which found that semiquantitative cultures from noninvasive samples did not alter mortality, days of mechanical ventilation, length of intensive care unit stay, or antibiotic use when compared with quantitative invasive strategies [<a href="#rid16">16</a>]. However, many of the included studies did not use a de-escalation strategy for antimicrobials which may have biased the data favoring the noninvasive strategy.</p><p>Endotracheal aspiration typically has the highest sensitivity for the diagnosis of VAP but lower specificity when compared with invasive strategies, which may potentially lead to the over diagnosis and over treatment of VAP; these data are discussed above. (See <a class="local">'Efficacy'</a> above.)</p><p class="headingAnchor" id="H1287472889"><span class="h2">Lung biopsy criteria</span><span class="headingEndMark"> — </span>Lung biopsy is <strong>not</strong> routinely performed in patients with suspected VAP since a diagnosis of VAP can be made in most patients using lower respiratory tract sampling and cultures. Lung biopsy may be reserved for patients in whom infiltrates are progressive despite antibiotic therapy or patients in whom a non-infectious etiology is suspected.</p><p>The purpose of acquiring tissue under these circumstances is to identify a pathogen that may have been missed with previous sampling or a pathogen that is difficult to culture (eg, fungus, herpes viruses) or to identify a noninfectious process masquerading as infection (eg, cancer, cryptogenic organizing pneumonitis, lymphangitis, interstitial pneumonitis, vasculitis).</p><p>Choosing between transthoracic needle, transbronchial, or thoracoscopic biopsy is often clinician-specific with most experts electing to perform thoracoscopic biopsy in ventilated patients. Biopsy in a ventilated patient is a high risk invasive procedure and the sensitivity is unknown. (See  <a class="medical medical_review" href="/d/html/15141.html" rel="external">"Overview of minimally invasive thoracic surgery"</a>.)</p><p class="headingAnchor" id="H3711040154"><span class="h2">Role of polymerase chain reaction techniques</span><span class="headingEndMark"> — </span>Molecular methods have evolved to assist in the rapid diagnosis and antimicrobial management of pathogens in patients with pneumonia including VAP [<a href="#rid48">48</a>]. However, they are not routinely or uniformly performed and test interpretation can be challenging. Polymerase chain reaction (PCR) is a fast and inexpensive technique that amplifies small segments of microbial DNA for identification. Multiplex PCR assays allow multiple tests to be performed simultaneously, which is important in critically ill patients where the list of potential pathogens can be broad. PCR methods can allow for the rapid identification of specific pathogens in respiratory samples facilitating both empiric antibiotic prescription and subsequent modification [<a href="#rid48">48-51</a>]. Commercially available multiplex PCR platforms are available and have demonstrated rapid and reasonably accurate detection of pathogens in patients with suspected VAP to facilitate antibiotic management [<a href="#rid52">52,53</a>]. Further study is needed to help identify for the clinician when and how PCR can be used.</p><p class="headingAnchor" id="H2756663"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>VAP is a clinical diagnosis made in a patient who has been mechanically ventilated for ≥48 hours who develops a new or progressive lung infiltrate on imaging with clinical evidence that the infiltrate is of infectious origin (eg, fever, purulent sputum, leukocytosis, and decline in oxygenation), together with a positive pathogen identified on microbiologic respiratory sample [<a href="#rid1">1,15</a>]. A positive microbiologic sample in a patient with a normal chest radiograph should raise the suspicion for tracheobronchitis. VAP cannot be confirmed or excluded until the culture results are complete, which generally takes two to three days; thus the diagnosis is retrospective during which time empiric therapy is ongoing. (See <a class="local">'Clinical definition of ventilator associated pneumonia'</a> below and  <a class="medical medical_review" href="/d/html/1644.html" rel="external">"Complications of the endotracheal tube following initial placement: Prevention and management in adult intensive care unit patients", section on 'Tracheobronchitis'</a>.)</p><p>Importantly, we and others do not include use of the entities of ventilator-associated conditions (VAC) and infection-related ventilator-associated complications (IVACs), which were introduced by the United States Centers for Disease Control and Prevention (CDC) for the purposes of surveillance and quality improvement [<a href="#rid54">54,55</a>]. These definitions do <strong>not</strong> aid diagnosis and treatment decisions for individual patients. (See <a class="local">'CDC definitions for ventilator associated events (VAE-VAC-IVAC-VAP)'</a> below.)</p><p>Common pathogens isolated in patients with VAP are <em>Staphylococcus aureus</em>, <em>Pseudomonas aeruginosa</em>, and other gram-negative bacilli. The Clinical Trials Transformation Initiative (CTTI) performed a prospective study in United States hospitals in 2016 [<a href="#rid56">56</a>]. Microbiologic testing was collected and recorded in 479 of 539 patients (89 percent) fulfilling study criteria for HAP and VAP in the ICU setting. A bacterial pathogen was identified from at least one source in 308 of the 479 specimens (64 percent). <em>Staphylococcus aureus </em>(22 percent of patients) and <em>Pseudomonas aeruginosa </em>(11 percent of patients)<em> </em>were the most frequently isolated bacterial pathogens individually with Enterobacterials being identified in 25 percent of patients. Common pathogens and their treatment are discussed separately. (See  <a class="medical medical_review" href="/d/html/7020.html" rel="external">"Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired and ventilator-associated pneumonia in adults", section on 'Microbiology'</a> and  <a class="medical medical_review" href="/d/html/6993.html" rel="external">"Treatment of hospital-acquired and ventilator-associated pneumonia in adults", section on 'Empiric therapy'</a>.)</p><p class="headingAnchor" id="H3999976606"><span class="h2">Clinical definition of ventilator associated pneumonia</span><span class="headingEndMark"> — </span>VAP is diagnosed when a patient who has been mechanically ventilated for ≥48 hours develops a new or progressive infiltrate with associated signs and symptoms of infection (eg, new onset of fever, purulent sputum, leukocytosis, decline in oxygenation, altered respiratory mechanics) (see <a class="local">'Clinical presentation'</a> above) in whom positive respiratory specimens are present (ie, increased neutrophils are seen in the microscopic analysis and growth of a pathogen in culture exceeds a predefined threshold). (See <a class="local">'Microscopic analysis and quantitative culture'</a> above and <a class="local">'Microscopic analysis and nonquantitative culture'</a> above.)</p><p class="headingAnchor" id="H1989663663"><span class="h2">CDC definitions for ventilator associated events (VAE-VAC-IVAC-VAP)</span><span class="headingEndMark"> — </span>The <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fnhsn%2Fpsc%2Fvae%2Findex.html%3FCDC_AA_refVal%3Dhttps%253A%252F%252Fwww.cdc.gov%252Fnhsn%252Facute-care-hospital%252Fvae%252Findex.html&amp;token=R4Uiw8%2FbmPVaqNHRDqpXLKgHrO9HtIJrGMVUGsRAMDDq54pNWXPZ0kurlkttFR1n08THQAYZpiDXIfLOYgebt7lt4vaqE%2B98vTFbGCP7IGjcOVw0q1HNBRt0F3RCmthuZgGudLgNYeLuuQXC9j8q%2Bw%3D%3D&amp;TOPIC_ID=1635" target="_blank">CDC National Healthcare Safety Network</a> implemented ventilator-associated events (VAE) surveillance in January 2013 [<a href="#rid54">54</a>]. This term was proposed to provide a more uniform and consistent manner of reporting cases of ventilator-associated complications. The definitions below are not intended to be used clinically so their impact on VAP prevention management is uncertain.</p><p>The VAE system is a three-tier surveillance definition that uses objective, readily available data to identify complications, including VAP, that occur in mechanically ventilated adult patients [<a href="#rid57">57,58</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ventilator-associated condition (VAC)</strong> – The first tier definition, VAC, identifies patients with a period of sustained respiratory deterioration (changes in positive end-expiratory pressure [PEEP] ≥3 cm H<sub>2</sub>O or fraction of inspired oxygen [FiO<sub>2</sub>] ≥0.2 [ie, 20 points] for two days) following a sustained period of stability or improvement on the ventilator (greater than or equal to two days)  (<a class="graphic graphic_algorithm graphicRef93247" href="/d/graphic/93247.html" rel="external">algorithm 2</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infection-related ventilator-associated complication (IVAC)</strong> – The second tier definition, IVAC, requires that patients with VAC also have an abnormal temperature (below 36°C or above 38°C) or white blood cell count (≤4000 or ≥12,000 cells/mm<sup>3</sup>) and be started on one or more new antibiotics that continue for four or more days  (<a class="graphic graphic_algorithm graphicRef93248" href="/d/graphic/93248.html" rel="external">algorithm 3</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Possible and probable VAP</strong> – The third tier definitions, possible and probable VAP, require that patients with IVAC also have laboratory and/or microbiological evidence of respiratory infection. Possible VAP is defined as Gram stain evidence of purulent pulmonary secretions or a pathogenic pulmonary culture in a patient with IVAC  (<a class="graphic graphic_algorithm graphicRef93249" href="/d/graphic/93249.html" rel="external">algorithm 4</a>). Probable VAP is defined as Gram stain evidence of purulence plus quantitative or semiquantitative growth of a pathogenic organism beyond specified thresholds  (<a class="graphic graphic_algorithm graphicRef93253" href="/d/graphic/93253.html" rel="external">algorithm 5</a>). Probable VAP can also be triggered by positive tests for respiratory viruses, Legionella species, pleural fluid cultures, and suggestive histopathology with or without an abnormal Gram stain result. (See <a class="local">'Clinical definition of ventilator associated pneumonia'</a> above.)</p><p></p><p>The effect of these criteria on clinical outcomes is unknown. One prospective study has reported that less than one-third of VAPs are identified by the VAE criteria and that most VAPs are non-preventable events [<a href="#rid58">58</a>]. In addition, patients with VAEs appear to have greater morbidity and mortality when compared with patients without a VAE.</p><p class="headingAnchor" id="H372662829"><span class="h2">Ventilated hospital-acquired pneumonia</span><span class="headingEndMark"> — </span>Ventilated hospital-acquired pneumonia (VHAP) represents pneumonia occurring in patients hospitalized for more than 48 hours with the <strong>subsequent</strong> need for mechanical ventilation [<a href="#rid1">1</a>]. The importance of VHAP is demonstrated by its greater overall prevalence, and in some studies greater mortality, compared with VAP [<a href="#rid1">1-4</a>]. In general, the epidemiology, pathogens, and outcomes of VHAP are more similar to VAP than hospital-acquired pneumonia (HAP) [<a href="#rid1">1,2,4</a>].</p><p class="headingAnchor" id="H1953349948"><span class="h1">THERAPEUTIC ADJUSTMENT AFTER CULTURE RESULTS</span><span class="headingEndMark"> — </span>Once cultures return, the patient should be re-evaluated to determine if additional diagnostic evaluation or changes in management are warranted. The following suggestions are ideal but a component of individualization and clinical judgement is necessary:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with positive cultures demonstrating pathogenic organisms who have improved on empiric therapy probably have VAP; the antimicrobial therapy should be pathogen-targeted. (See  <a class="medical medical_review" href="/d/html/6993.html" rel="external">"Treatment of hospital-acquired and ventilator-associated pneumonia in adults", section on 'Tailoring therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with positive cultures demonstrating pathogenic organisms who have not improved are still likely to have VAP but may have an explanation for lack of clinical improvement including inappropriate antimicrobial therapy or a complication of the VAP (eg, abscess, empyema) or a second source of infection. Alternatively, patients may have a noninfectious etiology for their symptoms. The antimicrobial regimen may need to be adjusted (eg, intensified regimen such as a second agent with improved pulmonary penetration), complication addressed (eg, drainage of pleural fluid), or other potential causes for failing to improve be sought (eg, additional sampling). (See <a class="local">'Differential diagnosis'</a> below and <a class="local">'Lung biopsy criteria'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with negative cultures who have improved are unlikely to have VAP assuming cultures were obtained prior to antimicrobial therapy and antimicrobial therapy should be discontinued. Some experts continue antibiotics empirically when cultures were taken after initiation of antimicrobial therapy and quickly de-escalate according to the clinical response and suspicion for VAP. (See  <a class="medical medical_review" href="/d/html/6993.html" rel="external">"Treatment of hospital-acquired and ventilator-associated pneumonia in adults", section on 'Tailoring therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with negative cultures who have not improved may or may not have VAP and further management should be individualized according to the suspicion for VAP; if cultures were obtained on antimicrobial therapy and the suspicion for VAP remains strong, antibiotics are frequently continued or altered. If the suspicion is low, then other diagnoses, sites of infection, or other organisms (eg, viruses or fungi) should be sought and the decision to continue antibiotic therapy individualized. In cases where antibiotics are continued, they should be stopped after no more than seven days.</p><p></p><p class="headingAnchor" id="H3407872614"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>There are many causes of pulmonary infiltrates, fever, respiratory abnormalities, and leukocytosis other than ventilator-associated pneumonia (VAP). The following conditions can present with this constellation of findings:</p><p class="bulletIndent1"><span class="glyph">●</span>Aspiration pneumonitis – Aspiration pneumonitis refers to chemical aspiration without infection; it is distinguished from VAP by history (ie, witnessed aspiration), microscopic analysis and culture of respiratory secretions (ie, negative), and clinical course (ie, self-limited). However, some cases of aspiration can be complicated by secondary infection. (See  <a class="medical medical_review" href="/d/html/7024.html" rel="external">"Aspiration pneumonia in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pulmonary embolism with infarction – Pulmonary embolism can mimic VAP if it causes pulmonary infarction; it is distinguished from VAP when imaging (eg, CT pulmonary angiography [CTPA]) reveals pulmonary embolism. (See  <a class="medical medical_review" href="/d/html/8261.html" rel="external">"Clinical presentation, evaluation, and diagnosis of the nonpregnant adult with suspected acute pulmonary embolism"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Acute respiratory distress syndrome – Acute respiratory distress syndrome (ARDS) is distinguished from VAP by history (ie, risk factors for ARDS may be present) and the microscopic analysis and culture of respiratory secretions (ie, negative). However, the two conditions may coexist. (See  <a class="medical medical_review" href="/d/html/1637.html" rel="external">"Acute respiratory distress syndrome: Clinical features, diagnosis, and complications in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pulmonary hemorrhage – Both pulmonary hemorrhage and VAP may cause hemoptysis. Pulmonary hemorrhage tends to present with frank bleeding while VAP often appears as blood mixed with purulent secretions, but this distinction is imperfect. Definitively distinguishing pulmonary hemorrhage from VAP requires that the cause of the hemoptysis be identified, typically on bronchoscopy. (See  <a class="medical medical_review" href="/d/html/4333.html" rel="external">"Evaluation of nonlife-threatening hemoptysis in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lung contusion – Pulmonary contusion is due to trauma, but it may be difficult to distinguish from VAP because the clinical and radiographic manifestations are similar and often delayed following the trauma. Pulmonary contusion is distinguished from VAP by history (ie, recent trauma) and the absence of organisms on microscopic analysis and culture of respiratory secretions. (See  <a class="medical medical_review" href="/d/html/7956.html" rel="external">"Overview of inpatient management of the adult trauma patient", section on 'Pulmonary contusion'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Infiltrative tumor – The manifestations of a diffuse infiltrative cancer are similar to VAP. Diffuse infiltrative cancer is distinguished from VAP by history (ie, history of malignancy); culture and microscopic analysis are negative but may be positive for malignant cells. Lung biopsy may be necessary. (See  <a class="medical medical_review" href="/d/html/8252.html" rel="external">"Pulmonary tumor embolism and lymphangitic carcinomatosis in adults: Diagnostic evaluation and management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Radiation pneumonitis – Radiation-induced lung injury may cause acute pneumonitis or chronic fibrosis. The former develops approximately 4 to 12 weeks after irradiation, with symptoms and signs that mimic VAP; it is distinguished from VAP by history (ie, prior irradiation) and negative microscopic analysis and culture of respiratory secretions. (See  <a class="medical medical_review" href="/d/html/4331.html" rel="external">"Radiation-induced lung injury"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Drug reaction – Pulmonary drug toxicity can result from many different drugs, most notably antineoplastic agents (eg, <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>). The clinical manifestations of pulmonary drug toxicity can be identical to VAP and the timing of the onset of symptoms and signs is highly variable (ie, days to months after receiving the medication). Pulmonary drug toxicity is distinguished from VAP by history (ie, received a potentially toxic agent within the past months) and negative microscopic analysis and culture of respiratory secretions. (See  <a class="medical medical_review" href="/d/html/4315.html" rel="external">"Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cryptogenic organizing pneumonia – Clinical features of cryptogenic organizing pneumonia (COP) may be identical to VAP; it is distinguished from VAP by history (ie, risk factors for COP may be present, such as a recent viral infection) and negative microscopic analysis and culture of respiratory secretions. Definitive diagnosis of COP requires lung biopsy. (See  <a class="medical medical_review" href="/d/html/4332.html" rel="external">"Cryptogenic organizing pneumonia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Vasculitis – Vasculitis (eg, systemic lupus erythematosus) is a rare cause of progressive pulmonary infiltrates that may present in a patients with a known diagnosis of an autoimmune disorder and can only be distinguished by biopsy.</p><p></p><p class="headingAnchor" id="H882837994"><span class="h1">TESTS OF LIMITED VALUE</span><span class="headingEndMark"> — </span>Biomarkers including procalcitonin, C-reactive protein (CRP), and soluble triggering receptor (sTREM-1), and the clinical pulmonary infection score (CPIS), are additional diagnostic tests that have been investigated. However, they have little role in the evaluation of suspected VAP [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H1591653120"><span class="h2">Biomarkers</span></p><p class="headingAnchor" id="H3152075454"><span class="h3">Procalcitonin</span><span class="headingEndMark"> — </span>Unlike patients with suspected community acquired pneumonia, where the role of procalcitonin can facilitate the decision to start antimicrobials, evidence is conflicting in patients with in <strong>suspected</strong> VAP [<a href="#rid59">59,60</a>]. Until higher quality studies resolve the uncertainty, we believe that serum procalcitonin levels should not be used for this purpose.</p><p>Procalcitonin may be useful in patients with <strong>confirmed</strong> VAP when making the decision to discontinue antibiotic therapy [<a href="#rid61">61</a>] and it may be a useful prognostic marker [<a href="#rid62">62-64</a>]. (See  <a class="medical medical_review" href="/d/html/114753.html" rel="external">"Procalcitonin use in lower respiratory tract infections", section on 'Ventilator-associated pneumonia'</a>.)</p><p class="headingAnchor" id="H274293891"><span class="h3">Others</span><span class="headingEndMark"> — </span>Other biomarkers, such as C-reactive protein (CRP) and soluble triggering receptor expressed on myeloid cells-1 (sTREM-1), were initially considered promising markers for improving diagnostic strategies for VAP. However, subsequent studies reported that the measurement of such biomarkers in BAL fluid has minimal diagnostic value [<a href="#rid65">65-67</a>].</p><p class="headingAnchor" id="H1111251295"><span class="h2">Clinical Pulmonary Infection Score (CPIS)</span><span class="headingEndMark"> — </span>The CPIS combines clinical, radiographic, physiologic, and microbiologic data into a numerical result  (<a class="graphic graphic_table graphicRef77054" href="/d/graphic/77054.html" rel="external">table 1</a>). Initial validation of the CPIS found that a score greater than six correlated with VAP [<a href="#rid68">68</a>]. However, subsequent studies failed to confirm this. In one prospective cohort study, the CPIS identified VAP with a sensitivity and specificity of only 60 and 59 percent, respectively [<a href="#rid69">69</a>].</p><p class="headingAnchor" id="H2574377441"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/109779.html" rel="external">"Society guideline links: Hospital-acquired pneumonia and ventilator-associated pneumonia in adults"</a>.)</p><p class="headingAnchor" id="H16"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Ventilator-associated pneumonia (VAP) is a type of hospital-acquired pneumonia that develops after 48 hours or more of mechanical ventilation. Patients with severe hospital-acquired pneumonia who require mechanical ventilation after the onset of infection do not meet the definition of VAP. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The presenting clinical findings of VAP are nonspecific with the gradual or sudden onset of a new or progressive pulmonary infiltrate on imaging and supportive clinical findings of infection including fever, purulent tracheobronchial secretions, leukocytosis, increased respiratory rate, decreased tidal volume, increased minute ventilation, and decreased oxygenation. Common radiographic abnormalities in VAP include alveolar infiltrates, air bronchograms, and silhouetting of adjacent solid organs. Clinical features alone are nonspecific for the diagnosis of VAP. (See <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with suspected VAP, most experts agree that the lower respiratory tract should be sampled and peripheral blood cultures should be sent obtained <strong>prior</strong> to the initiation of antibiotics or change of antibiotic therapy (in those already receiving antibiotics). Once the respiratory specimens have been obtained, empiric antibiotic therapy should be administered. (See <a class="local">'Respiratory tract sampling'</a> above and <a class="local">'Timing of sampling and empiric antibiotics'</a> above and  <a class="medical medical_review" href="/d/html/6993.html" rel="external">"Treatment of hospital-acquired and ventilator-associated pneumonia in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Experts disagree on how the respiratory sample should be obtained (invasively or noninvasively) and whether or not cultures should be quantitative or nonquantitative. No approach has demonstrated superiority over the other with regards to clinical outcomes including mortality or length of stay. (See <a class="local">'Respiratory tract sample type'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We favor invasive sampling methods (eg, mini-bronchoalveolar lavage [BAL], bronchoscopic BAL, or protected specimen brush [PSB]) with quantitative cultures rather than noninvasive sampling (ie, endotracheal aspiration) with nonquantitative cultures. This preference is based upon the high value that we place on diagnostic accuracy and the potential to reduce antibiotic exposure, thereby promoting good antibiotic stewardship. (See <a class="local">'Our preferred approach'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Noninvasive sampling using endotracheal aspiration with semiquantitative cultures is an acceptable alternative approach. While this approach is less invasive, it may over diagnose VAP and potentially lead to inappropriate use of antimicrobials. (See <a class="local">'Alternative approach'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Practice varies widely and is often institution-, physician-, and patient-specific. Factors that influence the decision include ability of the patient to tolerate invasive sampling, the presence of other indications for bronchoscopy, available expertise, and cost.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Procalcitonin and other biomarkers such as C-reactive protein (CRP) and soluble triggering receptor (sTREM-1) are not recommended. Lung biopsy is <strong>no</strong>t routinely performed but may be reserved for patients in whom infiltrates are progressive despite antibiotic therapy or patients in whom a noninfectious etiology is suspected. (See <a class="local">'Tests of limited value'</a> above and <a class="local">'Lung biopsy criteria'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>VAP is a clinical diagnosis based upon the identification a new or progressive lung infiltrate on imaging with clinical evidence that the infiltrate is of infectious origin (eg, fever, purulent sputum, leukocytosis, and decline in oxygenation), together with a positive pathogen identified on microbiologic respiratory sample. VAP cannot be confirmed or excluded until the culture results are complete, which generally takes two to three days. Once cultures return, the patient should be reevaluated to determine if additional diagnostic evaluation or changes in management are warranted. (See <a class="local">'Diagnosis'</a> above and <a class="local">'Therapeutic adjustment after culture results'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There are many causes of pulmonary infiltrates, fever, respiratory abnormalities, and leukocytosis other than VAP. These include aspiration pneumonitis, pulmonary embolism with infarction, acute respiratory distress syndrome, pulmonary hemorrhage, pulmonary contusion, infiltrative tumor, radiation pneumonitis, pulmonary drug toxicity, cryptogenic organizing pneumonia (COP), and vasculitis. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Kalil AC, Metersky ML, Klompas M, et al. Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 2016; 63:e61.</a></li><li><a class="nounderline abstract_t">Torres A, Niederman MS, Chastre J, et al. International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: Guidelines for the management of hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociación Latinoamericana del Tórax (ALAT). Eur Respir J 2017; 50.</a></li><li><a class="nounderline abstract_t">Ibn Saied W, Mourvillier B, Cohen Y, et al. A Comparison of the Mortality Risk Associated With Ventilator-Acquired Bacterial Pneumonia and Nonventilator ICU-Acquired Bacterial Pneumonia. Crit Care Med 2019; 47:345.</a></li><li><a class="nounderline abstract_t">Micek ST, Chew B, Hampton N, Kollef MH. A Case-Control Study Assessing the Impact of Nonventilated Hospital-Acquired Pneumonia on Patient Outcomes. Chest 2016; 150:1008.</a></li><li><a class="nounderline abstract_t">Meduri GU. Diagnosis and differential diagnosis of ventilator-associated pneumonia. Clin Chest Med 1995; 16:61.</a></li><li><a class="nounderline abstract_t">Fagon JY, Chastre J, Hance AJ, et al. Evaluation of clinical judgment in the identification and treatment of nosocomial pneumonia in ventilated patients. Chest 1993; 103:547.</a></li><li><a class="nounderline abstract_t">Wunderink RG, Woldenberg LS, Zeiss J, et al. The radiologic diagnosis of autopsy-proven ventilator-associated pneumonia. Chest 1992; 101:458.</a></li><li><a class="nounderline abstract_t">Stefanidis K, Moser J, Vlahos I. Imaging of Diffuse Lung Disease in the Intensive Care Unit Patient. Radiol Clin North Am 2020; 58:119.</a></li><li><a class="nounderline abstract_t">Staub LJ, Biscaro RRM, Maurici R. Accuracy and Applications of Lung Ultrasound to Diagnose Ventilator-Associated Pneumonia: A Systematic Review. J Intensive Care Med 2018; 33:447.</a></li><li><a class="nounderline abstract_t">Pradhan S, Shrestha PS, Shrestha GS, Marhatta MN. Clinical impact of lung ultrasound monitoring for diagnosis of ventilator associated pneumonia: A diagnostic randomized controlled trial. J Crit Care 2020; 58:65.</a></li><li><a class="nounderline abstract_t">Torres A, el-Ebiary M, Padró L, et al. Validation of different techniques for the diagnosis of ventilator-associated pneumonia. Comparison with immediate postmortem pulmonary biopsy. Am J Respir Crit Care Med 1994; 149:324.</a></li><li><a class="nounderline abstract_t">Dotson RG, Pingleton SK. The effect of antibiotic therapy on recovery of intracellular bacteria from bronchoalveolar lavage in suspected ventilator-associated nosocomial pneumonia. Chest 1993; 103:541.</a></li><li><a class="nounderline abstract_t">Chastre J, Fagon JY, Bornet-Lecso M, et al. Evaluation of bronchoscopic techniques for the diagnosis of nosocomial pneumonia. Am J Respir Crit Care Med 1995; 152:231.</a></li><li><a class="nounderline abstract_t">Timsit JF, Misset B, Renaud B, et al. Effect of previous antimicrobial therapy on the accuracy of the main procedures used to diagnose nosocomial pneumonia in patients who are using ventilation. Chest 1995; 108:1036.</a></li><li><a class="nounderline abstract_t">Erb CT, Patel B, Orr JE, et al. Management of Adults with Hospital-acquired and Ventilator-associated Pneumonia. Ann Am Thorac Soc 2016; 13:2258.</a></li><li><a class="nounderline abstract_t">Berton DC, Kalil AC, Teixeira PJ. Quantitative versus qualitative cultures of respiratory secretions for clinical outcomes in patients with ventilator-associated pneumonia. Cochrane Database Syst Rev 2014; :CD006482.</a></li><li><a class="nounderline abstract_t">Corley DE, Kirtland SH, Winterbauer RH, et al. Reproducibility of the histologic diagnosis of pneumonia among a panel of four pathologists: analysis of a gold standard. Chest 1997; 112:458.</a></li><li><a class="nounderline abstract_t">Pham LH, Brun-Buisson C, Legrand P, et al. Diagnosis of nosocomial pneumonia in mechanically ventilated patients. Comparison of a plugged telescoping catheter with the protected specimen brush. Am Rev Respir Dis 1991; 143:1055.</a></li><li><a class="nounderline abstract_t">Marik PE, Brown WJ. A comparison of bronchoscopic vs blind protected specimen brush sampling in patients with suspected ventilator-associated pneumonia. Chest 1995; 108:203.</a></li><li><a class="nounderline abstract_t">Papazian L, Thomas P, Garbe L, et al. Bronchoscopic or blind sampling techniques for the diagnosis of ventilator-associated pneumonia. Am J Respir Crit Care Med 1995; 152:1982.</a></li><li><a class="nounderline abstract_t">Rouby JJ, Martin De Lassale E, Poete P, et al. Nosocomial bronchopneumonia in the critically ill. Histologic and bacteriologic aspects. Am Rev Respir Dis 1992; 146:1059.</a></li><li><a class="nounderline abstract_t">Kollef MH, Bock KR, Richards RD, Hearns ML. The safety and diagnostic accuracy of minibronchoalveolar lavage in patients with suspected ventilator-associated pneumonia. Ann Intern Med 1995; 122:743.</a></li><li><a class="nounderline abstract_t">Marquette CH, Georges H, Wallet F, et al. Diagnostic efficiency of endotracheal aspirates with quantitative bacterial cultures in intubated patients with suspected pneumonia. Comparison with the protected specimen brush. Am Rev Respir Dis 1993; 148:138.</a></li><li><a class="nounderline abstract_t">el-Ebiary M, Torres A, González J, et al. Quantitative cultures of endotracheal aspirates for the diagnosis of ventilator-associated pneumonia. Am Rev Respir Dis 1993; 148:1552.</a></li><li><a class="nounderline abstract_t">Marquette CH, Copin MC, Wallet F, et al. Diagnostic tests for pneumonia in ventilated patients: prospective evaluation of diagnostic accuracy using histology as a diagnostic gold standard. Am J Respir Crit Care Med 1995; 151:1878.</a></li><li><a class="nounderline abstract_t">Jourdain B, Novara A, Joly-Guillou ML, et al. Role of quantitative cultures of endotracheal aspirates in the diagnosis of nosocomial pneumonia. Am J Respir Crit Care Med 1995; 152:241.</a></li><li><a class="nounderline abstract_t">Sanchez-Nieto JM, Torres A, Garcia-Cordoba F, et al. Impact of invasive and noninvasive quantitative culture sampling on outcome of ventilator-associated pneumonia: a pilot study. Am J Respir Crit Care Med 1998; 157:371.</a></li><li><a class="nounderline abstract_t">Fagon JY, Chastre J, Wolff M, et al. Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia. A randomized trial. Ann Intern Med 2000; 132:621.</a></li><li><a class="nounderline abstract_t">Rello J, Vidaur L, Sandiumenge A, et al. De-escalation therapy in ventilator-associated pneumonia. Crit Care Med 2004; 32:2183.</a></li><li><a class="nounderline abstract_t">Kollef MH. Diagnosis of ventilator-associated pneumonia. N Engl J Med 2006; 355:2691.</a></li><li><a class="nounderline abstract_t">Pieracci FM, Rodil M, Haenel J, et al. Screening for Ventilator-Associated Pneumonia in the Surgical Intensive Care Unit: A Single-Institution Analysis of 1,013 Lower Respiratory Tract Cultures. Surg Infect (Larchmt) 2015; 16:368.</a></li><li><a class="nounderline abstract_t">Sharpe JP, Magnotti LJ, Weinberg JA, et al. Adherence to an established diagnostic threshold for ventilator-associated pneumonia contributes to low false-negative rates in trauma patients. J Trauma Acute Care Surg 2015; 78:468.</a></li><li><a class="nounderline abstract_t">Artuk C, Gül HC, Mert G, et al. [Comparison of endotracheal aspiration and mini-BAL culture results in the diagnosis of ventilator-associated pneumonia]. Mikrobiyol Bul 2012; 46:421.</a></li><li><a class="nounderline abstract_t">Tepper J, Johnson S, Parker C, et al. Comparing the Accuracy of Mini-BAL to Bronchoscopic BAL in the Diagnosis of Pneumonia Among Ventilated Patients: A Systematic Literature Review. J Intensive Care Med 2023; 38:1099.</a></li><li><a class="nounderline abstract_t">Sirvent JM, Vidaur L, Gonzalez S, et al. Microscopic examination of intracellular organisms in protected bronchoalveolar mini-lavage fluid for the diagnosis of ventilator-associated pneumonia. Chest 2003; 123:518.</a></li><li><a class="nounderline abstract_t">Kirtland SH, Corley DE, Winterbauer RH, et al. The diagnosis of ventilator-associated pneumonia: a comparison of histologic, microbiologic, and clinical criteria. Chest 1997; 112:445.</a></li><li><a class="nounderline abstract_t">Wimberley N, Faling LJ, Bartlett JG. A fiberoptic bronchoscopy technique to obtain uncontaminated lower airway secretions for bacterial culture. Am Rev Respir Dis 1979; 119:337.</a></li><li><a class="nounderline abstract_t">Baselski VS, el-Torky M, Coalson JJ, Griffin JP. The standardization of criteria for processing and interpreting laboratory specimens in patients with suspected ventilator-associated pneumonia. Chest 1992; 102:571S.</a></li><li><a class="nounderline abstract_t">Baker AM, Bowton DL, Haponik EF. Decision making in nosocomial pneumonia. An analytic approach to the interpretation of quantitative bronchoscopic cultures. Chest 1995; 107:85.</a></li><li><a class="nounderline abstract_t">Timsit JF, Misset B, Goldstein FW, et al. Reappraisal of distal diagnostic testing in the diagnosis of ICU-acquired pneumonia. Chest 1995; 108:1632.</a></li><li><a class="nounderline abstract_t">Canadian Critical Care Trials Group. A randomized trial of diagnostic techniques for ventilator-associated pneumonia. N Engl J Med 2006; 355:2619.</a></li><li><a class="nounderline abstract_t">Solé Violán J, Fernández JA, Benítez AB, et al. Impact of quantitative invasive diagnostic techniques in the management and outcome of mechanically ventilated patients with suspected pneumonia. Crit Care Med 2000; 28:2737.</a></li><li><a class="nounderline abstract_t">Bonten MJ, Bergmans DC, Stobberingh EE, et al. Implementation of bronchoscopic techniques in the diagnosis of ventilator-associated pneumonia to reduce antibiotic use. Am J Respir Crit Care Med 1997; 156:1820.</a></li><li><a class="nounderline abstract_t">Timsit JF. Bronchoalveolar lavage for VAP diagnosis: patients must be sampled before any change of antimicrobial therapy. Intensive Care Med 2007; 33:1690.</a></li><li><a class="nounderline abstract_t">Trupka T, Fisher K, Micek ST, et al. Enhanced antimicrobial de-escalation for pneumonia in mechanically ventilated patients: a cross-over study. Crit Care 2017; 21:180.</a></li><li><a class="nounderline abstract_t">Shorr AF, Sherner JH, Jackson WL, Kollef MH. Invasive approaches to the diagnosis of ventilator-associated pneumonia: a meta-analysis. Crit Care Med 2005; 33:46.</a></li><li><a class="nounderline abstract_t">Ewig S, Niederman M, Torres A. Management of suspected ventilator-associated pneumonia. Ann Intern Med 2000; 133:1008.</a></li><li><a class="nounderline abstract_t">Guillamet MCV, Burnham JP, Kollef MH. Novel Approaches to Hasten Detection of Pathogens and Antimicrobial Resistance in the Intensive Care Unit. Semin Respir Crit Care Med 2019; 40:454.</a></li><li><a class="nounderline abstract_t">Kollef MH, Burnham CD. Ventilator-Associated Pneumonia: The Role of Emerging Diagnostic Technologies. Semin Respir Crit Care Med 2017; 38:253.</a></li><li><a class="nounderline abstract_t">Trevino SE, Pence MA, Marschall J, et al. Rapid MRSA PCR on respiratory specimens from ventilated patients with suspected pneumonia: a tool to facilitate antimicrobial stewardship. Eur J Clin Microbiol Infect Dis 2017; 36:879.</a></li><li><a class="nounderline abstract_t">Conway Morris A, Gadsby N, McKenna JP, et al. 16S pan-bacterial PCR can accurately identify patients with ventilator-associated pneumonia. Thorax 2017; 72:1046.</a></li><li><a class="nounderline abstract_t">Lee SH, Ruan SY, Pan SC, et al. Performance of a multiplex PCR pneumonia panel for the identification of respiratory pathogens and the main determinants of resistance from the lower respiratory tract specimens of adult patients in intensive care units. J Microbiol Immunol Infect 2019; 52:920.</a></li><li><a class="nounderline abstract_t">Gadsby NJ, McHugh MP, Forbes C, et al. Comparison of Unyvero P55 Pneumonia Cartridge, in-house PCR and culture for the identification of respiratory pathogens and antibiotic resistance in bronchoalveolar lavage fluids in the critical care setting. Eur J Clin Microbiol Infect Dis 2019; 38:1171.</a></li><li><a class="nounderline abstract_t">Klompas M. Complications of mechanical ventilation--the CDC's new surveillance paradigm. N Engl J Med 2013; 368:1472.</a></li><li><a class="nounderline abstract_t">Hayashi Y, Morisawa K, Klompas M, et al. Toward improved surveillance: the impact of ventilator-associated complications on length of stay and antibiotic use in patients in intensive care units. Clin Infect Dis 2013; 56:471.</a></li><li class="breakAll">Kollef MH, Washington University, 2020, personal data.</li><li><a class="nounderline abstract_t">Magill SS, Klompas M, Balk R, et al. Developing a new, national approach to surveillance for ventilator-associated events*. Crit Care Med 2013; 41:2467.</a></li><li><a class="nounderline abstract_t">Boyer AF, Schoenberg N, Babcock H, et al. A prospective evaluation of ventilator-associated conditions and infection-related ventilator-associated conditions. Chest 2015; 147:68.</a></li><li><a class="nounderline abstract_t">Ramirez P, Garcia MA, Ferrer M, et al. Sequential measurements of procalcitonin levels in diagnosing ventilator-associated pneumonia. Eur Respir J 2008; 31:356.</a></li><li><a class="nounderline abstract_t">Luyt CE, Combes A, Reynaud C, et al. Usefulness of procalcitonin for the diagnosis of ventilator-associated pneumonia. Intensive Care Med 2008; 34:1434.</a></li><li><a class="nounderline abstract_t">Stolz D, Smyrnios N, Eggimann P, et al. Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study. Eur Respir J 2009; 34:1364.</a></li><li><a class="nounderline abstract_t">Luyt CE, Guérin V, Combes A, et al. Procalcitonin kinetics as a prognostic marker of ventilator-associated pneumonia. Am J Respir Crit Care Med 2005; 171:48.</a></li><li><a class="nounderline abstract_t">Seligman R, Meisner M, Lisboa TC, et al. Decreases in procalcitonin and C-reactive protein are strong predictors of survival in ventilator-associated pneumonia. Crit Care 2006; 10:R125.</a></li><li><a class="nounderline abstract_t">Hillas G, Vassilakopoulos T, Plantza P, et al. C-reactive protein and procalcitonin as predictors of survival and septic shock in ventilator-associated pneumonia. Eur Respir J 2010; 35:805.</a></li><li><a class="nounderline abstract_t">Linssen CF, Bekers O, Drent M, Jacobs JA. C-reactive protein and procalcitonin concentrations in bronchoalveolar lavage fluid as a predictor of ventilator-associated pneumonia. Ann Clin Biochem 2008; 45:293.</a></li><li><a class="nounderline abstract_t">Anand NJ, Zuick S, Klesney-Tait J, Kollef MH. Diagnostic implications of soluble triggering receptor expressed on myeloid cells-1 in BAL fluid of patients with pulmonary infiltrates in the ICU. Chest 2009; 135:641.</a></li><li><a class="nounderline abstract_t">Fagon JY. Biological markers and diagnosis of ventilator-associated pneumonia. Crit Care 2011; 15:130.</a></li><li><a class="nounderline abstract_t">Pugin J, Auckenthaler R, Mili N, et al. Diagnosis of ventilator-associated pneumonia by bacteriologic analysis of bronchoscopic and nonbronchoscopic "blind" bronchoalveolar lavage fluid. Am Rev Respir Dis 1991; 143:1121.</a></li><li><a class="nounderline abstract_t">Fartoukh M, Maitre B, Honoré S, et al. Diagnosing pneumonia during mechanical ventilation: the clinical pulmonary infection score revisited. Am J Respir Crit Care Med 2003; 168:173.</a></li></ol></div><div id="topicVersionRevision">Topic 1635 Version 36.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27418577" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28890434" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: Guidelines for the management of hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociación Latinoamericana del Tórax (ALAT).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30407949" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : A Comparison of the Mortality Risk Associated With Ventilator-Acquired Bacterial Pneumonia and Nonventilator ICU-Acquired Bacterial Pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27102181" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : A Case-Control Study Assessing the Impact of Nonventilated Hospital-Acquired Pneumonia on Patient Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7768095" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Diagnosis and differential diagnosis of ventilator-associated pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8432152" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Evaluation of clinical judgment in the identification and treatment of nosocomial pneumonia in ventilated patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1735272" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The radiologic diagnosis of autopsy-proven ventilator-associated pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31731896" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Imaging of Diffuse Lung Disease in the Intensive Care Unit Patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29084483" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Accuracy and Applications of Lung Ultrasound to Diagnose Ventilator-Associated Pneumonia: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32361220" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Clinical impact of lung ultrasound monitoring for diagnosis of ventilator associated pneumonia: A diagnostic randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8306025" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Validation of different techniques for the diagnosis of ventilator-associated pneumonia. Comparison with immediate postmortem pulmonary biopsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8432151" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The effect of antibiotic therapy on recovery of intracellular bacteria from bronchoalveolar lavage in suspected ventilator-associated nosocomial pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7599829" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Evaluation of bronchoscopic techniques for the diagnosis of nosocomial pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7555116" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Effect of previous antimicrobial therapy on the accuracy of the main procedures used to diagnose nosocomial pneumonia in patients who are using ventilation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27925784" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Management of Adults with Hospital-acquired and Ventilator-associated Pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25354013" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Quantitative versus qualitative cultures of respiratory secretions for clinical outcomes in patients with ventilator-associated pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9266884" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Reproducibility of the histologic diagnosis of pneumonia among a panel of four pathologists: analysis of a gold standard.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2024814" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Diagnosis of nosocomial pneumonia in mechanically ventilated patients. Comparison of a plugged telescoping catheter with the protected specimen brush.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7606959" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : A comparison of bronchoscopic vs blind protected specimen brush sampling in patients with suspected ventilator-associated pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8520766" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Bronchoscopic or blind sampling techniques for the diagnosis of ventilator-associated pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1416397" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Nosocomial bronchopneumonia in the critically ill. Histologic and bacteriologic aspects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7717596" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : The safety and diagnostic accuracy of minibronchoalveolar lavage in patients with suspected ventilator-associated pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8317789" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Diagnostic efficiency of endotracheal aspirates with quantitative bacterial cultures in intubated patients with suspected pneumonia. Comparison with the protected specimen brush.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8256899" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Quantitative cultures of endotracheal aspirates for the diagnosis of ventilator-associated pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7767535" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Diagnostic tests for pneumonia in ventilated patients: prospective evaluation of diagnostic accuracy using histology as a diagnostic gold standard.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7599831" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Role of quantitative cultures of endotracheal aspirates in the diagnosis of nosocomial pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9476845" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Impact of invasive and noninvasive quantitative culture sampling on outcome of ventilator-associated pneumonia: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10766680" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia. A randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15640629" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : De-escalation therapy in ventilator-associated pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17182995" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Diagnosis of ventilator-associated pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26207397" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Screening for Ventilator-Associated Pneumonia in the Surgical Intensive Care Unit: A Single-Institution Analysis of 1,013 Lower Respiratory Tract Cultures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25710415" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Adherence to an established diagnostic threshold for ventilator-associated pneumonia contributes to low false-negative rates in trauma patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22951654" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : [Comparison of endotracheal aspiration and mini-BAL culture results in the diagnosis of ventilator-associated pneumonia].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37545322" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Comparing the Accuracy of Mini-BAL to Bronchoscopic BAL in the Diagnosis of Pneumonia Among Ventilated Patients: A Systematic Literature Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12576375" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Microscopic examination of intracellular organisms in protected bronchoalveolar mini-lavage fluid for the diagnosis of ventilator-associated pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9266883" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : The diagnosis of ventilator-associated pneumonia: a comparison of histologic, microbiologic, and clinical criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/375784" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : A fiberoptic bronchoscopy technique to obtain uncontaminated lower airway secretions for bacterial culture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1424932" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : The standardization of criteria for processing and interpreting laboratory specimens in patients with suspected ventilator-associated pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7813319" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Decision making in nosocomial pneumonia. An analytic approach to the interpretation of quantitative bronchoscopic cultures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7497774" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Reappraisal of distal diagnostic testing in the diagnosis of ICU-acquired pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17182987" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : A randomized trial of diagnostic techniques for ventilator-associated pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10966244" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Impact of quantitative invasive diagnostic techniques in the management and outcome of mechanically ventilated patients with suspected pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9412561" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Implementation of bronchoscopic techniques in the diagnosis of ventilator-associated pneumonia to reduce antibiotic use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17673973" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Bronchoalveolar lavage for VAP diagnosis: patients must be sampled before any change of antimicrobial therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28709439" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Enhanced antimicrobial de-escalation for pneumonia in mechanically ventilated patients: a cross-over study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15644647" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Invasive approaches to the diagnosis of ventilator-associated pneumonia: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11119406" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Management of suspected ventilator-associated pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31585472" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Novel Approaches to Hasten Detection of Pathogens and Antimicrobial Resistance in the Intensive Care Unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28578550" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Ventilator-Associated Pneumonia: The Role of Emerging Diagnostic Technologies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28004323" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Rapid MRSA PCR on respiratory specimens from ventilated patients with suspected pneumonia: a tool to facilitate antimicrobial stewardship.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27974525" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : 16S pan-bacterial PCR can accurately identify patients with ventilator-associated pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31806539" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Performance of a multiplex PCR pneumonia panel for the identification of respiratory pathogens and the main determinants of resistance from the lower respiratory tract specimens of adult patients in intensive care units.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30859358" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Comparison of Unyvero P55 Pneumonia Cartridge, in-house PCR and culture for the identification of respiratory pathogens and antibiotic resistance in bronchoalveolar lavage fluids in the critical care setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23594002" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Complications of mechanical ventilation--the CDC's new surveillance paradigm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23118272" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Toward improved surveillance: the impact of ventilator-associated complications on length of stay and antibiotic use in patients in intensive care units.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23118272" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Toward improved surveillance: the impact of ventilator-associated complications on length of stay and antibiotic use in patients in intensive care units.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24162674" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Developing a new, national approach to surveillance for ventilator-associated events*.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24854003" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : A prospective evaluation of ventilator-associated conditions and infection-related ventilator-associated conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17959634" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Sequential measurements of procalcitonin levels in diagnosing ventilator-associated pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18421435" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Usefulness of procalcitonin for the diagnosis of ventilator-associated pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19797133" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15447947" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Procalcitonin kinetics as a prognostic marker of ventilator-associated pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16956405" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Decreases in procalcitonin and C-reactive protein are strong predictors of survival in ventilator-associated pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19717486" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : C-reactive protein and procalcitonin as predictors of survival and septic shock in ventilator-associated pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18482918" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : C-reactive protein and procalcitonin concentrations in bronchoalveolar lavage fluid as a predictor of ventilator-associated pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18849395" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Diagnostic implications of soluble triggering receptor expressed on myeloid cells-1 in BAL fluid of patients with pulmonary infiltrates in the ICU.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21418551" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Biological markers and diagnosis of ventilator-associated pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2024824" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Diagnosis of ventilator-associated pneumonia by bacteriologic analysis of bronchoscopic and nonbronchoscopic "blind" bronchoalveolar lavage fluid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12738607" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Diagnosing pneumonia during mechanical ventilation: the clinical pulmonary infection score revisited.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
